Suchergebnisse - "Dalal, Rahul S"

PubPharm (9)

1

1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure

enthalten in: Inflammatory bowel diseases | 2024

von Dalal, R. | Sharma, P. | Bains, K. | +2

2

Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis : A Multicenter Retrospective Cohort Study

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2024

von Dalal, R. | Kallumkal, G. | Cabral, H. | +3

3

Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases

enthalten in: Inflammatory bowel diseases | 2023

von Dalal, R. | Pruce, J. | Allegretti, J.

4

Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis : A Multicenter Cohort Study

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Dalal, R. | Esckilsen, S. | Barnes, E. | +3

5

Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders

enthalten in: Inflammatory bowel diseases | 2022

von Dalal, R. | Gupta, S. | Goodrick, H. | +2

6

Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis : A Propensity Score Analysis

enthalten in: Inflammatory bowel diseases | 2021

von Dalal, R. | Mitri, J. | Goodrick, H. | +1

7

Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification

enthalten in: Inflammatory bowel diseases | 2021

von Dalal, R. | Njie, C. | Marcus, J. | +2

CommentIn: Inflamm Bowel Dis. 2021 May 17;27(6):e69. - PMID 33570129

8

Ustekinumab Dose Optimization in Crohn Disease : One Size Does Not Fit All

enthalten in: Inflammatory bowel diseases | 2021

von Dalal, R. | Allegretti, J.

CommentOn: Inflamm Bowel Dis. 2021 Jul 27;27(8):1294-1301. - PMID 33146703

9

Two Strikes but Not Out : Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab

enthalten in: Digestive diseases and sciences | 2021

von Dalal, R. | Ananthakrishnan, A. | Hamilton, M. | +1

1
[1]